This session highlights the critical role of intracoronary imaging in evaluating acute coronary syndromes (ACS). It discusses the management of complex lesion morphologies involving calcium and thrombus, the diagnostic power of OCT in decision-making, challenges beyond angiography in right coronary artery pathology, and the identification of...

This session reviews key sub-studies from major TAVI trials that extend beyond primary endpoints to provide a deeper understanding of valve performance and patient outcomes. It covers comparisons between balloon-expandable and self-expanding valves, long-term real-world data on the Myval valve, echocardiographic outcomes, composite endpoint analyses, and...

This session focuses on the diagnosis and management of ischemia and angina with non-obstructive coronary arteries (INOCA and ANOCA). It presents safety data from coronary function testing, patient outcomes after comprehensive ischemia assessment, and endotype-specific treatment effects. Further topics include coronary sinus reducer therapy, the impact...

This session highlights new evidence in coronary physiology related to microvascular assessment. Topics include endothelial dysfunction in angina with non-obstructive arteries, the prognostic value of microvascular resistance metrics, natural history studies, and trials aimed at standardizing management of microvascular dysfunction.

Martin Bergmann reviews the evolving evidence for LAAC, examining how recent landmark trials such as OPTION, CLOSURE‑AF and CHAMPION‑AF are reshaping patient selection and expanding the role of LAAC across a broader spectrum of patients with atrial fibrillation.

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.

Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.